Dr. Taieb Discusses Sidedness in Metastatic Colon Cancer

Julien Taieb, MD
Published: Friday, Nov 10, 2017



Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses sidedness in metastatic colon cancer.

Taieb states that disease-free survival with no recurrence is not impacted by sidedness. Conversely, if a patient relapses, the survival after relapse is clearly impacted by sidedness with right-sided tumors having a poorer prognosis.

For patients who are BRAF and KRAS mutant, it seems that having a right-sided tumor is a good prognostic factor, Taieb adds.
 


Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses sidedness in metastatic colon cancer.

Taieb states that disease-free survival with no recurrence is not impacted by sidedness. Conversely, if a patient relapses, the survival after relapse is clearly impacted by sidedness with right-sided tumors having a poorer prognosis.

For patients who are BRAF and KRAS mutant, it seems that having a right-sided tumor is a good prognostic factor, Taieb adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x